Aducanumab Approved As The First New Drug Therapy For Alzheimer's Patients In 18 Years
Two recent articles showed showed changes in the focus and funding of clinical trials for Alzheimer's disease therapies.
And they suggested the change might be evidenced by today, when the U.S. Food and Drug Administration (FDA) seemed ready to approve aducanumab (Biogen) as the first new drug therapy to Alzheimer's patients in nearly 20 years.
Namely the emergence of taxpayer-funded government and nonprofit organizations as the primary drivers of research.
Alzheimer's is difficult and when a company is looking at a billion dollar expense to navigate the red tape of modern FDA approval…